New biopharma company Fusion scores $33 mln Series A round
Fusion Pharmaceuticals Inc, a newly-formed Canadian biopharmaceutical company, has raised about $33 million (US$25 million) in a Series A financing. The round was led by Johnson & Johnson Innovation-JJDC Inc and joined by HealthCap, TPG Biotech, Genesys Capital and FACIT. Hamilton, Ontario's Fusion is a spin-out from the Centre for Probe Development and Commercialization, located at McMaster University. Led by that organization's founder, Dr. John Valliant, Fusion is focused on developing targeted radiotherapeutics for treating cancer. It will use the funds raised to bring its lead program, FPX-01, into human clinical trials.
23 February 2017•5 mins read
